Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Inhaled murepavadin

Phase One

Phase One

Therapeutic Approach

Anti-Infective

This program is studying an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. An inhaled version could make it easier for someone with a Pseudomonas infection to take the drug from home. In addition, the drug, which targets the outer membrane of bacteria, has the potential to be a once-a-day treatment.

Status

A phase 1b/2a trial is planned to study inhaled murepavadin in adults with CF.

Sponsor

This program is sponsored by Polyphor and partially funded by the Cystic Fibrosis Foundation.



Contact us about Inhaled murepavadin >